Skip to main content

Table 4 Clinical characteristics and echocardiographic variables of patients with or without cardiovascular event

From: Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction

Parameters

(-) (n = 43)

Cardiovascular event

 

(+) (n = 38)

p value

Age

58 ± 17

66 ± 15

0.037

1)

Male

36

28

0.289

2)

NYHA functional class III-IV

6

12

0.067

2)

IHD

10

10

0.800

2)

Rhythm (Af / pacing)

10

17

0.059

2)

BNP (pg/mL)

580 ± 805

965 ± 903

0.005

3)

Total bilirubin (mg/dL)

0.93 ± 0.53

1.34 ± 0.98

0.018

1)

Uric acid (mg/dL)

7.08 ± 1.89

7.76 ± 3.18

0.235

1)

eGFR (mL/min/1.73 m2)

55.8 ± 18.9

44.9 ± 19.8

0.015

1)

Hemoglobin (g/dL)

14.3 ± 2.3

13.5 ± 1.9

0.081

1)

C-reactive protein (mg/dL)

1.4 ± 3.0

1.5 ± 2.9

0.039

3)

LAD (cm)

3.89 ± 0.66

4.43 ± 0.91

0.003

1)

IVSTd (cm)

1.08 ± 0.35

0.87 ± 0.24

0.004

1)

LVPWTd (cm)

1.11 ± 0.27

1.01 ± 0.21

0.070

1)

LVDd (cm)

6.06 ± 0.79

6.22 ± 1.25

0.465

1)

LVDs (cm)

5.28 ± 0.85

5.50 ± 1.28

0.356

1)

LVEF (%)

31.4 ± 7.6

28.5 ± 7.8

0.093

1)

RVOT-FS

0.38 ± 0.20

0.27 ± 0.17

0.008

1)

RVFAC (%)

38 ± 14

32 ± 14

0.086

1)

TR-PG (mmHg)

25 ± 14

25 ± 9

0.978

1)

Beta-blocker

25

29

0.102

2)

ACE-I/ARB

28

30

0.219

2)

Calcium channel blocker

11

6

0.413

2)

Diuretic

24

36

<0.0001

2)

Aldosterone antagonist

21

25

0.177

2)

  1. Values are expressed as absolute number or the mean ± SD. Each variable was analyzed by 1) unpaired t-test, 2) Fisher's exact test and 3) Mann-Whitney test.
  2. NYHA New York Heart Association, IHD ischemic heart disease, Af atrial fibrillation, BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, LA left atrial dimension (diastole), IVSTd intraventricular septal wall thickness (diastole), LVPWTd left ventricular posterior wall thickness (diastole), LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, RVFAC right ventricular fractional area change, TR-PG tricuspid regurgitation-pressure gradient, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II type 1 receptor antagonist.